GF
ALNY icon

Gries Financial’s Alnylam Pharmaceuticals ALNY Stock Holding History

Gries Financial’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$229K Buy
+502
New +$204K 0.04% 288

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Gries Financial's ALNY Position: Q3 2025 in Review

Gries Financial opened a new position in Alnylam Pharmaceuticals (ALNY) in Q3 2025: 502 shares worth $229K. The stake represents 0.04% of the portfolio and ranks #288 among its holdings.

823 funds tracked by Wall St. Rank hold ALNY as of Q3 2025.

  • Gries Financial held 502 shares of Alnylam Pharmaceuticals worth $229K as of Q3 2025.
  • Alnylam Pharmaceuticals was a new Gries Financial position in Q3 2025.
  • Alnylam Pharmaceuticals made up 0.04% of Gries Financial's portfolio in Q3 2025, its #288 holding.
  • 823 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2025.

Based on Gries Financial's 13F filing for Q3 2025, filed 22 Oct 2025.